Division of Pharmaceutical Science, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, United States.
Int J Pharm. 2011 Jul 29;414(1-2):77-85. doi: 10.1016/j.ijpharm.2011.05.001. Epub 2011 May 7.
In order to improve oral absorption, a novel prodrug of saquinavir (Saq), ascorbyl-succinic-saquinavir (AA-Su-Saq) targeting sodium dependent vitamin C transporter (SVCT) was synthesized and evaluated. Aqueous solubility, stability and cytotoxicity were determined. Affinity of AA-Su-Saq towards efflux pump P-glycoprotein (P-gp) and recognition of AA-Su-Saq by SVCT were studied. Transepithelial permeability across polarized MDCK-MDR1 and Caco-2 cells were determined. Metabolic stability of AA-Su-Saq in rat liver microsomes was investigated. AA-Su-Saq appears to be fairly stable in both DPBS and Caco-2 cells with half lives of 9.65 and 5.73 h, respectively. Uptake of [(3)H]Saquinavir accelerated by 2.7 and 1.9 fold in the presence of 50 μM Saq and AA-Su-Saq in MDCK-MDR1 cells. Cellular accumulation of [(14)C]AA diminished by about 50-70% relative to control in the presence of 200 μM AA-Su-Saq in MDCK-MDR1 and Caco-2 cells. Uptake of AA-Su-Saq was lowered by 27% and 34% in the presence of 5mM AA in MDCK-MDR1 and Caco-2 cells, respectively. Absorptive permeability of AA-Su-Saq was elevated about 4-5 fold and efflux index reduced by about 13-15 fold across the polarized MDCK-MDR1 and Caco-2 cells. Absorptive permeability of AA-Su-Saq decreased 44% in the presence of 5mM AA across MDCK-MDR1 cells. AA-Su-Saq was devoid of cytotoxicity over the concentration range studied. AA-Su-Saq significantly enhanced the metabolic stability but lowered the affinity towards CYP3A4. In conclusion, prodrug modification of Saq through conjugation to AA via a linker significantly raised the absorptive permeability and metabolic stability. Such modification also caused significant evading of P-gp mediated efflux and CYP3A4 mediated metabolism. SVCT targeted prodrug approach can be an attractive strategy to enhance the oral absorption and systemic bioavailability of anti-HIV protease inhibitors.
为了提高口服吸收,我们合成并评价了一种新型的沙奎那韦前药(Saq),即抗坏血酸琥珀酸沙奎那韦(AA-Su-Saq),该前药靶向钠离子依赖维生素 C 转运体(SVCT)。测定了其水溶解度、稳定性和细胞毒性。研究了 AA-Su-Saq 对流出泵 P-糖蛋白(P-gp)的亲和力和对 SVCT 的识别。测定了跨极化 MDCK-MDR1 和 Caco-2 细胞的跨上皮通透性。研究了 AA-Su-Saq 在大鼠肝微粒体中的代谢稳定性。AA-Su-Saq 在 DPBS 和 Caco-2 细胞中均相当稳定,半衰期分别为 9.65 和 5.73 h。在存在 50 μM Saq 和 AA-Su-Saq 的情况下,MDCK-MDR1 细胞中 [(3)H]沙奎那韦的摄取分别加速了 2.7 倍和 1.9 倍。在存在 200 μM AA-Su-Saq 的情况下,MDCK-MDR1 和 Caco-2 细胞中 [(14)C]AA 的细胞积累相对于对照减少了约 50-70%。在 MDCK-MDR1 和 Caco-2 细胞中,分别存在 5mM AA 时,AA-Su-Saq 的摄取降低了 27%和 34%。在极化的 MDCK-MDR1 和 Caco-2 细胞中,AA-Su-Saq 的吸收渗透性分别提高了约 4-5 倍,外排指数降低了约 13-15 倍。在存在 5mM AA 的情况下,MDCK-MDR1 细胞中 AA-Su-Saq 的吸收渗透性降低了 44%。在研究浓度范围内,AA-Su-Saq 无细胞毒性。AA-Su-Saq 显著提高了代谢稳定性,但降低了对 CYP3A4 的亲和力。总之,通过将 AA 通过连接子与 Saq 缀合,对 Saq 进行前药修饰,可显著提高吸收渗透性和代谢稳定性。这种修饰还导致 P-gp 介导的外排和 CYP3A4 介导的代谢显著逃逸。SVCT 靶向前药方法可能是提高抗 HIV 蛋白酶抑制剂口服吸收和系统生物利用度的一种有吸引力的策略。